Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October

August 2, 2021
Takeda Pharmaceutical’s group revenue in April-June rose 18.4% year on year, pushed up by the divestment of diabetes assets in Japan. Fourteen global brands fared strongly, while profits jumped sharply thanks to a decrease in outlays related to its 2019...read more